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Background: Patients surviving stroke but who have significant impairment of function in the affected arm are at
more risk of developing pain, stiffness and contractures. The abnormal muscle activity, associated with post-stroke
spasticity, is thought to be causally associated with the development of these complications. Treatment of spasticity
is currently delayed until a patient develops signs of these complications.
Methods/Design: This protocol is for a phase II study that aims to identify whether using OnabotulinumtoxinA
(BoNT-A) in combination with physiotherapy early post stroke when initial abnormal muscle activity is
neurophysiologically identified can prevent loss of range at joints and improve functional outcomes.
The trial uses a screening phase to identify which people are appropriate to be included in a double blind
randomised placebo-controlled trial. All patients admitted to Sandwell and West Birmingham NHS Trust Hospitals
with a diagnosis of stroke will be screened to identify functional activity in the arm. Those who have no function
will be appropriate for further screening. Patients who are screened and have abnormal muscle activity identified
on EMG will be given electrical stimulation to forearm extensors for 3 months and randomised to have either
injections of BoNT-A or normal saline. The primary outcome measure is the action research arm test - a measure of
arm function. Further measures include spasticity, stiffness, muscle strength and fatigue as well as measures of
quality of life, participation and caregiver strain.
Trial registrations: ISRCTN57435427, EudraCT2010-021257-39, NCT01882556
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Stroke is a common cause of disability and is a signifi-
cant contributor to loss of independence [1]. Those who
have not recovered some level of useful function in the
acute stages (within 4 to 6 weeks of the stroke) are at
more risk of developing long-term musculoskeletal com-
plications such as contractures and pain [2-4]. It is gen-
erally believed that the lack of functional recovery and
these secondary complications result from the develop-
ment of spasticity, that is, intermittent or sustained invol-
untary activation of muscles [5] that normally precedes
the development of these secondary complications.* Correspondence: Camlin3@hotmail.com
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stated.The management of spasticity is complex and nor-
mally involves multiple professions [6]. Rehabilitation
therapies are generally eclectic and are aimed at prevent-
ing the secondary complications and reducing aggravat-
ing factors rather than the abnormal muscle activity
itself [6]. Treatment of spasticity, in current practice, is
delayed until secondary complications are established. It
is possible that deterioration in the musculoskeletal im-
pairments before the initiation of spasticity treatment
may be detrimental to the patient as these musculoskel-
etal changes may have become too chronic and impos-
sible to fully eradicate [7].
This study will evaluate the benefit of early treatment
with OnabotulinumtoxinA (BoNT-A) when added to
standard care therapies, in patients suffering from post-
stroke upper limb spasticity, which is identified in its
early stages by clinical and neurophysiological markers.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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the combination of decreasing the abnormal muscle ac-
tivity of forearm flexors results in greater functional re-
covery than increasing the extensor activity alone.Methods and design
Objectives
Primary objective
To evaluate the clinical effects of BoNT-A and physio-
therapy when compared with placebo and physiotherapy,
in patients with focal spasticity post stroke, identified on
clinical and neurophysiological grounds, in facilitating
the recovery of arm function (measured using the Action
Research Arm Test (ARAT)).Secondary objectives
1. To evaluate the effectiveness of BoNT-A and
physiotherapy when compared with placebo and
physiotherapy in patients with focal spasticity, post
stroke, identified on clinical and neurophysiological
grounds.
2. To reduce focal spasticity in the arm as measured by
surface EMG response of the wrist and elbow
flexors to an externally imposed perturbation.
3. To improve strength and fatigue as measured by
maximum isometric strength and the rate of force
production in the wrist and elbow joints.
4. To reduce stiffness and increase passive range
of movement by measuring the range of
movement and force required to produce the
movement with a custom built device.
5. To reduce post-stroke pain measured using a visual
analogue scale.
6. To improve quality of life (using the EuroQol Group
EQ5D) and assess care giver burden (using the Care
Giver Burden Scale).
7. To reduce the need for additional oral anti-
spasmodic drugs or additional botulinum treatment
during the course of rehabilitation.
8. To reduce long-term costs (quantified using resource
utilisation diaries) and identify discharge destination.Study design
This study combines a screening phase to identify ap-
propriate subjects to enter a phase II, double blind, ran-
domised, placebo-controlled trial. Final follow-up will be
at 6 months following stroke.Ethics
This study was approved by North West - Greater Manchester
South Ethics Committee Reference number 10/H1003/111.Recruitment
All patients admitted to the Trust with a diagnosis of
stroke will be eligible to participate. Patients will be
identified as potential candidates for recruitment during
the initial (standard practice) assessment by the Stroke
Physician or Physiotherapist. Patients and relatives will
then be approached by the Trial Clinician. A decision will
be made on the patient’s capacity to consent 24 hours
after initially being approached by the Trial Clinician. In
cases where the patient lacks capacity a legal representa-
tive will provide consent.
Inclusion criteria to screening phase
 Over 18 years of age.
 Patients admitted to hospital with a diagnosis of
stroke (between days 1 and 42) due to a primary
cerebral haemorrhage/infarction or subarachnoid
haemorrhage producing an upper motor syndrome
affecting one body side which results in a
hemiplegia.
 Capable of providing informed consent directly or
indirectly, or, consent obtainable from next of kin or
legal representative.
 No useful arm function (Defined as less than or
equal to 2 on the grasp subsection of the ARAT) at
onset of spasticity.
Eligibility for randomisation to treatment phase of study
To be eligible for the treatment phase of the study pa-
tients will have to meet the following additional criteria.
 Evidence of upper limb spasticity demonstrated by a
muscle response during a passive stretch of a
relaxed muscle.
Exclusion criteria
 Significant musculoskeletal conditions that affected
upper limb function prior to the stroke (for example,
pre-existing contractures).
 Unconscious or moribund during the screening
period.
 Recovery of useful arm function (a score of 3 or
more in the grasp section of the ARAT) prior to
injections.
 Patients with contraindications to electrical
stimulation including active implants (for example,
cardiac assist devices), metal implants at site of
stimulation, scar tissue/cancerous tissue at site of
stimulation, uncontrolled epilepsy, deep vein
thrombosis in limb/muscle being stimulated and
pregnancy (or planned pregnancy). These will be
dealt with on a case-by-case basis.
Table 1 OnabotulinumtoxinA units for muscles to be
injected
Muscle Units (−25%) Main dose units Units (+25%)
Biceps 30 40 50
Brachialis 30 40 50
Flexor digitorum
superficialis
20 25 30
Flexor digitorum
profundus
20 25 30
Flexor carpi ulnaris 10 15 20
Flexor carpi radialis 10 15 20
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hypertonicity due to multiple sclerosis, spinal cord
injury or other neurological disorder.
 Patients with a known hypersensitivity to any
BoNT-A or to any of the excipients of BoNT-A
(for example, human serum albumin).
 Patients with myasthenia gravis or Eaton Lambert
syndrome or other neuromuscular junction or
myopathic disorder.
 Patients with infection at the proposed injection site(s).
 Patients who are pregnant or may become pregnant
at the time of the proposed injections and for the
duration of the study.
 Current treatment with any anti-spasticity agent or
previous injection with BoNT-A.
Screening phase
From the date of consent, Patients who are enrolled in
the study will be monitored for a period of 6 weeks from
stroke onset by an independent assessor (the study ther-
apist). Monitoring will normally be carried out every
other day excluding weekends. The frequency will be in-
creased to daily if clinically indicated. For monitoring
purposes the therapist will conduct two simple bedside
tests: (1) the grasp subsection of the ARAT; and (2) the
surface EMG response of the wrist and elbow flexors
to a passive externally imposed stretch. (Non-invasive
EMG electrodes will be placed on the elbow flexors and
wrist flexors.) The joint limb will be moved from full
flexion to extension a maximum of six times from a pos-
ition of rest. Presence of spasticity will be a velocity related
increase in muscle activity. Patient positioning will be doc-
umented as sitting or half lying.
Study groups
During the screening phase, patients will be categorised
into one of the three following groups depending on
their presentation.
Group one: the patient recovers function. On recovery
of function a full set of baseline measures will be taken
and follow-up at 3 and 6 months will be planned.
Group two: the patient develops no abnormal muscle
activity in the first 42 days following the stroke. At day
42 a full set of baseline measures will be taken and
follow-up at 3 and 6 months will be planned.
Group three: the patient develops abnormal muscle ac-
tivity and no functional recovery has occurred. The pa-
tient will have a full set of baseline measures taken and
then be randomised.
Randomisation phase
Interventions
All eligible patients were randomised to receive I.M. in-
jections of BoNT-A or 0.9% sodium chloride solution to6 muscles of the affected arm in predetermined doses.
Muscles that will be injected are flexor digitorum super-
ficialis, flexor digitorum profundus, flexor carpi ulnaris,
flexor carpi radialis, biceps and brachialis. The volume
to inject will be calculated on the number of units per
mL that the injection solution would contain if it con-
tained BoNT-A. Table 1 shows the OnabotulinumtoxinA
units to be administered to each muscle. In patients with
a substantial lack or excess of muscle bulk or where
there is excessive muscle activity leading to clonus larger
or smaller doses will be administered (as shown in
Table 1) at the discretion of the research clinician.Randomisation method
Randomisation was by computer-generated random per-
muted blocks in a pseudorandom sequence.Blinding
The research clinician will complete the prescription form
and, following assessment of the patient by a Consultant,
the prescription will be signed by the Consultant. The
prescription will then be taken to pharmacy where ei-
ther two vials of BoNT-A and one 5 mL ampoule of
0.9% sodium dhloride solution (Treatment group) or
only the one 5 mL ampoule of 0.9% sodium chloride
solution (Placebo group), depending on the random-
isation, will be dispensed.
The dispensed drug will be taken to the ward in a
sealed opaque bag where an independent clinician will
fill the syringes with either the reconstituted toxin in
solution or solution alone depending on the random-
isation. A second trained clinician will be in attendance
to confirm the syringes were filled with dispensed prod-
uct. Separate sharps bins will be used for preparation/
reconstitution and injecting. This will ensure that the
patient and injector will remain blinded to treatment.
Localisation of the involved muscles will be deter-
mined by electrical stimulation techniques. Where local-
isation of the muscles for injection is not clear using
EMG then ultrasound should be employed to guide the
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the needle in the specified muscles.
Outcome measurements
Arm function was measured using the ARAT [8]. The
measure will be carried out by a single researcher at
baseline, 3 months post injection and 6 months post
stroke using the standardised approach advocated by
Yozbatriran et al. [9].
Measures of spasticity and contractures
Spasticity in the wrist and elbow flexors will be quanti-
fied by measuring the muscle activity and stiffness, dur-
ing an externally imposed stretch of a relaxed muscle.
Two stretch velocities will be used. In addition to quan-
tifying spasticity (from the EMG data) and contractures
(stiffness) from the data collected during this procedure
it will be possible to quantify passive range of movement
and the data required to provide a Tardieu Score related
to spasticity. A flexible electrogoniometer will be placed
on the lateral border across the wrist or elbow - this al-
lows for non-invasive measurement of joint range of
movement.
These measurements were taken using the following
standardised protocol. Surface EMG electrodes will be
placed in accordance with European recommended sites
for the biceps and long head of triceps [10].
The electrodes will be placed on the forearm flexor
and extensor muscles using bony landmarks to identify
location as follows:
Forearm flexor muscles - In a line between the medial
epicondyle of the humerus and medial border of the bi-
ceps tendon - from the mid-point of this line the elec-
trodes will be attached approximately one-third of the
length of the forearm. With the arm in full pronation
the electrode is placed one-third of the distance between
the lateral epicondyle of the humerus and the radial
styloid.
The therapist will move the joint from full flexion to full
extension, using two manually controlled velocities, a max-
imum of six times. The data will be collected using a Data-
Log (Biometrics Ltd.). Following transfer to a computer,
the data will be interrogated to produce measurements of
spasticity and joint stiffness. Patient position will be uni-
form at all measurements. This measurement protocol has
been used in previous trials [11,12].
These measures will be taken at baseline, 2, 4 and 6
weeks and 3 months post injections and finally at 6
months post stroke.
Pain will be measured using a visual analogue scale at
baseline, 3 months and 6 months.
Muscle function will be quantified by measuring iso-
metric strength at mid-range of movement using a dyna-
mometer. A grip dynamometer will measure grip strength.(Fatigue will be derived from the above measurement of
strength by estimating the time taken for the force gener-
ation to drop to 70% of the maximum isometric strength
measurement). These measures will be taken at baseline,
3 months and 6 months.
The Barthel index will be measured at baseline, 3 months
and 6 months [13]. While it was originally devised to assess
the individual’s capacity to carry out physical tasks, it has
subsequently become used as a measure of activity.
Measure of quality of life using the EuroQuol EQ5D
will be taken at 3 and 6 months. The EuroQuol EQ-5D-
5 L is a health-related measure of quality of life measur-
ing five dimensions: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. While the simi-
lar but older version (5D-3 L) with just three levels of
problem has been used extensively in stroke, the newer
version with five levels has been used less so.
A measure of care giver burden will be taken at 6
months using the Care Giver Strain Index (CGSI) as will
the modified Rankin scale. The CGSI was first developed
by Robinson (1983) and has been used widely with
stroke survivors’ families and carers [14].
Planned statistical analysis
The study team will assess the data collected for all pa-
tients at a review meeting to determine the suitability of
each patient in the analysis populations prior to breaking
the blind for the whole group. AE reporting will be based
on the intention to treat population.
All-available-patient (AAP) population
All patients who have consented for the study will be
used for patient accountability and listings and will in-
clude patients who are randomised but who do not re-
ceive their injection of study medication.
Intent-to-treat (ITT) population: All patients who have
been randomised and received their injection of study
medication at baseline will be included in an ITT popu-
lation (missing values will be dealt with using standard
procedure in current use). All patients included in the
ITT population, who participate in the study, without
major protocol violation.
The study team with guidance from a medical statisti-
cian and health economist will assess the data collected
for all patients at a review meeting to determine the suit-
ability of each patient in the analysis populations prior to
breaking the blind for the whole group. AE reporting will
be based on the ITT population.
Demographic and background data will be summarised
using appropriate summary statistics. Effects of treatment
will be estimated using effect size calculations (difference
between groups divided by the pooled standard deviation)
and 95% confidence interval of the effect size for all
continuous variables and odds ratio with 95% confidence
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example, pain).
Sample size calculations
Sample size calculations have been identified using data
from a pilot study [12]. With an effect size of 0.5 and at
80% power (0.05) significance level 126 patients will be
required. With an effect size of 0.6 and at 80% power
(0.05) significance level 88 patients will be required.
Allowing for an attrition of 20% the maximum number of
participants we will need is 150 and the minimum is 88.
All available patients who have consented for the study
will be used for patient accountability and listings and
will include patients who are randomised but who do
not receive their injection of study medication.
All patients who have been randomised and received
their injection of study medication at baseline will be in-
cluded in an ITT population (missing values will be
dealt with using standard procedure in current use).
Dissemination plan
The results of the trial, regardless of outcome, will be
disseminated through the traditional routes of scientific
peer-reviewed publications, international and national
specialist conferences, and the Stroke Research Network.
CL will be responsible for initially drafting these manu-
scripts and professional writers will not be used for any
of the publications. Authorship will be based on the cri-
teria defined by the International Committee of Medical
Journal Editors [15]. We aim to be able to compose the
final results paper within 4 months of the unblinding
procedure occurring. Subjects who have been involved
in the trial will be given the option of having a summary
of the results sent to them.
Trial status
Recruitment began in February 2012 and is due to end
in December 2013.
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